64 related articles for article (PubMed ID: 37889870)
1. Immune checkpoint inhibitor use, multimorbidity and healthcare expenditures among older adults with late-stage melanoma.
Rai P; Shen C; Kolodney J; Kelly KM; Scott VG; Sambamoorthi U
Immunotherapy; 2021 Feb; 13(2):103-112. PubMed ID: 33148082
[No Abstract] [Full Text] [Related]
2. Geographic disparity in the distribution of cancer clinical trials in the United States and the associated factors.
Gu N; Elsisi Z; Suk R; Li M
J Manag Care Spec Pharm; 2024 Apr; 30(4):376-385. PubMed ID: 38555628
[TBL] [Abstract][Full Text] [Related]
3. Disparity in initiation of checkpoint inhibitors among commercially insured and Medicare Advantage patients with metastatic melanoma.
Li M; Liao K; Nowakowska M; Wehner M; Shih YT
J Manag Care Spec Pharm; 2023 Nov; 29(11):1232-1241. PubMed ID: 37889870
[No Abstract] [Full Text] [Related]
4. Disparity in checkpoint inhibitor utilization among commercially insured adult patients with metastatic lung cancer.
Li M; Liao K; Chen AJ; Cascone T; Shen Y; Lu Q; Shih YT
J Natl Cancer Inst; 2023 Mar; 115(3):295-302. PubMed ID: 36346180
[TBL] [Abstract][Full Text] [Related]
5. Association Between Sex and Immune Checkpoint Inhibitor Outcomes for Patients With Melanoma.
Jang SR; Nikita N; Banks J; Keith SW; Johnson JM; Wilson M; Lu-Yao G
JAMA Netw Open; 2021 Dec; 4(12):e2136823. PubMed ID: 34854905
[TBL] [Abstract][Full Text] [Related]
6. Immune-Related Adverse Events After Immune Checkpoint Inhibitors for Melanoma Among Older Adults.
Schonfeld SJ; Tucker MA; Engels EA; Dores GM; Sampson JN; Shiels MS; Chanock SJ; Morton LM
JAMA Netw Open; 2022 Mar; 5(3):e223461. PubMed ID: 35315916
[TBL] [Abstract][Full Text] [Related]
7. Association of Medicaid Expansion With Mortality Disparity by Race and Ethnicity Among Patients With De Novo Stage IV Breast Cancer.
Malinowski C; Lei X; Zhao H; Giordano SH; Chavez-MacGregor M
JAMA Oncol; 2022 Jun; 8(6):863-870. PubMed ID: 35389432
[TBL] [Abstract][Full Text] [Related]
8. Management of metastatic melanoma in Texas: disparities in the utilization of immunotherapy following the regulatory approval of immune checkpoint inhibitors.
Olateju OA; Zeng Z; Thornton JD; Mgbere O; Essien EJ
BMC Cancer; 2023 Jul; 23(1):655. PubMed ID: 37442992
[TBL] [Abstract][Full Text] [Related]
9. Immune checkpoint inhibitors as first line in advanced melanoma: Evaluating progression-free survival based on reconstructed individual patient data.
Ossato A; Damuzzo V; Baldo P; Mengato D; Chiumente M; Messori A
Cancer Med; 2023 Feb; 12(3):2155-2165. PubMed ID: 35920297
[TBL] [Abstract][Full Text] [Related]
10. Skin Cancer in People of Color: A Systematic Review.
Zakhem GA; Pulavarty AN; Lester JC; Stevenson ML
Am J Clin Dermatol; 2022 Mar; 23(2):137-151. PubMed ID: 34902111
[TBL] [Abstract][Full Text] [Related]
11. Epidemiology of Melanoma.
Saginala K; Barsouk A; Aluru JS; Rawla P; Barsouk A
Med Sci (Basel); 2021 Oct; 9(4):. PubMed ID: 34698235
[TBL] [Abstract][Full Text] [Related]
12. Health Care Spending And Use Among Hispanic Adults With And Without Limited English Proficiency, 1999-2018.
Himmelstein J; Himmelstein DU; Woolhandler S; Bor DH; Gaffney A; Zallman L; Dickman S; McCormick D
Health Aff (Millwood); 2021 Jul; 40(7):1126-1134. PubMed ID: 34228521
[TBL] [Abstract][Full Text] [Related]
13. Immune-Based Cancer Treatment: Addressing Disparities in Access and Outcomes.
Osarogiagbon RU; Sineshaw HM; Unger JM; Acuña-Villaorduña A; Goel S
Am Soc Clin Oncol Educ Book; 2021 Mar; 41():1-13. PubMed ID: 33830825
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
